Please ensure Javascript is enabled for purposes of website accessibility

The Results of This Marijuana Study May Leave You a Bit Grumpy

By Sean Williams - Jan 10, 2016 at 10:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

According to this study from researchers at Yale and Pennsylvania State, marijuana may lead to a surprising change in behavior among users.

Image source: Flickr user oswaldo.

Marijuana legalization has advanced by leaps and bounds over the past two decades, but 2016 could really be the year that it jumps into the spotlight.

This is a critical year for marijuana
Since receiving its first medical approval in the state of California in 1996, medical marijuana has been approved in 22 additional states. We've even witnessed voters in four states (along with Washington, D.C.) legalize the use of recreational marijuana for adults ages 21 and up. Over a period of two decades that's some pretty substantial progress for the industry.

But 2016 could prove even bigger for the pot industry. Nevada has already secured enough signatures to get a recreational marijuana initiative on its ballot in the 2016 elections, and California, the largest economy in the U.S., looks poised to have a recreational marijuana initiative on its ballot as well. In fact, we could be looking at residents in around a dozen states voting on recreational marijuana amendments and initiatives in November.

The potential passage of recreational marijuana laws is critical -- President Obama has suggested that the best way to get Congress's attention is through the steady legalization of marijuana at the state level. Although marijuana remains an illegal plant at the federal level, the federal government is perfectly fine (for now) with allowing states to handle regulating the drug on their own. If more states legalize marijuana, it could force Congress to act.

Image source: Pixabay.

It all comes down to safety
The big concern for lawmakers is, and has always been, marijuana's safety profile. Considering that for decades the majority of clinical studies have focused on the possible adverse effects of marijuana rather than potential benefits, there's simply an overwhelming stack of evidence against marijuana at the moment. Congress seems unwilling to bend on its current stance until it has a more thorough and balanced picture of marijuana's benefits and risks.

Of course, there is certainly no shortage of longtime users who'll jump at the chance to inform skeptics of marijuana's potential health benefits and lack of long-term risks. The simple fact that not a single person in the U.S. died of a marijuana overdose in 2014 is testament that it could be beneficial in medical patients looking to resolve certain ailments that might otherwise require the use of prescription opioids -- which lead to approximately 17,000 deaths annually in the U.S. due to overdose.

We're also witnessing clinical evidence that marijuana and/or its cannabinoids may hold the key to improved quality of life for a number of ailments. Patients with two rare forms of childhood epilepsy -- Dravet syndrome and Lennox-Gastaut syndrome -- demonstrated a greater than 50% reduction in seizure frequency when taking GW Pharmaceuticals' experimental cannabinoid-based drug Epidiolex. Other early stage studies have suggested marijuana could hold benefits for cancer patients, type 2 diabetics, and even Alzheimer's disease patients.

Image source: Flickr user bark.

This new study may leave you a bit grumpy
However, not every new study has worked in favor of marijuana supporters. Initially published online in January 2015, a study from researchers at the Yale University of Medicine and Pennsylvania State University showed that trial participants who smoked marijuana tended to be more hostile and impulsive the day they used marijuana, as well as the day after.

According to Yale and Pennsylvania State researchers, 43 trial participants were analyzed over a 14-day period to determine how they responded to marijuana, alcohol, and tobacco. After controlling for certain factors, and removing alcohol and tobacco from the equation, researchers observed that marijuana users demonstrated an increase in hostile and impulsive behavior the day they used the drug and the following day. The ultimate conclusion of these researchers was that the behavioral impact of marijuana warrants additional research, especially in light of the expansion of recreational marijuana in some states. 

It is worth noting that 43 patients can hardly be described as representative of the U.S. adult population, which totaled roughly 245 million people as of 2014. Just because marijuana users in this small sample proved more hostile, it doesn't guarantee that marijuana was the cause, which is why additional studies are needed. Nonetheless, it does place yet another obstacle in marijuana's possible path to nationwide legalization.

Image source: GW Pharmaceuticals.

Owning marijuana stocks could make you even grumpier
If marijuana is eventually legalized at the federal level, its market potential could be huge. ArcView Group placed a market value of $2.7 billion on the marijuana industry as of 2014, while Greenwave Advisors has separately suggested that nationwide legalization could pump up the legal marijuana industry to a $35 billion valuation within a few years. These figures have dollars signs dancing in the heads of investors, some of whom believe that marijuana could be one of the top investments of the next decade.

Unfortunately for investors, marijuana stocks look to be just as dangerous an investment today as they've been in the past. The reason is that state-level legalization doesn't do much to counter the disadvantages marijuana businesses face at the federal level. Marijuana businesses have practically no access to credit lines or basic banking services because banks don't want to face potential federal prosecution for aiding a business involved in a federally illicit drug. Marijuana businesses also get no help come tax time since they're unable to take any deductions like normal businesses.

These challenges make it very difficult for large-scale, investable marijuana businesses to turn healthy profits. If the federal government were to change its stance, my view on marijuana as an investment would almost assuredly change as well -- but there's simply no guarantee that the federal government will change its stand anytime soon. Waiting around simply isn't an option for some marijuana companies, which are losing money hand-over-fist -- which makes this industry a very risky investment that I'd suggest completely avoiding.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.